CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF DRUG REGISTRATION APPLICATION FOR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (CRM197, TT VECTOR)

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the National Medical Products Administration (the "**NMPA**") of the People's Republic of China has recently granted a notice of acceptance to the Company's new drug application for registration and marketing of domestic manufactured drugs for its 13-Valent pneumococcal conjugate vaccine (CRM197, TT Vector) (the "**PCV13*i***") developed by the Company.

Our PCV13*i* adopts a covalent combination of polysaccharide antigens and carrier proteins. After the polysaccharide antigens are linked to the carrier proteins, the polysaccharide can be converted into T cells dependent antigens, which not only induces a high level of specific antibodies in infants and young children under 2 years old, but also generates memory B cells to produce immune memory. Meanwhile, the Company adopts double vector technology which can reduce the immunosuppression to immunogenicity when co-injecting with other vaccines. In terms of production technology, the Company has adopted a safer production process, with animal-free culture medium as the fermentation medium, reducing risks from animal-derived biological factors and avoiding the toxicity residue from traditional purification process by phenol method.

After the acceptance of drug registration application for PCV13*i* with NMPA, PCV13*i* shall be subject to the procedures of technical evaluation, clinical trial onsite inspection and production site inspection, and will be commercialized only after obtaining the new drug application (the "**NDA**") approval and lot release approval. The progress of the evaluation and approval of PCV13*i* and the date of obtaining the NDA approval are subject to uncertainties. Upon the commercialization of PCV13*i*, it will have a positive impact on the operating results, enrich the pipeline and further enhance the competitiveness of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 28, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive directors, Ms. Nisa Bernice Wing-Yu LEUNG as a non-executive director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive directors.